Takeda Pharmaceutical Company

Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression

The Phase 2 failure in major depressive disorder marks the second time in a little more than a year that Neurocrine Biosciences has reported a drug licensed from Takeda Pharmaceutical fell short in the clinic. Last year, a different drug from this partnership failed a mid-stage test in schizophrenia.

By Frank Vinluan

BioPharma

Takeda strikes $1B RNAi deal with Arrowhead Pharmaceuticals

The companies will partner on development and commercialization of ARO-AAT, Arrowhead's Phase II RNA-interference drug for alpha-1 antitrypsin-associated liver disease, a rare genetic disorder. An analyst wrote that the deal makes sense given Takeda's position in the AAT-augmentation therapy market.

By Alaric DeArment